SVB Leerink initiated coverage of Axcella Health (NASDAQ:AXLA) with an “outperform” rating and a $21 price target. The stock closed at $14.27 on May 31.

Roth Capital Partners launched coverage of Atara Biotherapeutics (NASDAQ:ATRA) with a “buy” rating and price target of $30. The stock closed at $23.30 on May 29.

Roth Capital Partners initiated coverage of Marker Therapeutics (NASDAQ:MRKR) with a “buy” rating and $10 price target. The stock closed at $5.91 on May 29.

Roth Capital Partners initiated coverage of Forty Seven (NASDAQ:FTSV) with a “buy” rating and $28 price target. The stock closed at $12.49, up 34 cents, on May 28.

Roth Capital Partners launched coverage of Five Prime Therapeutics (NASDAQ:FPRX) with a “neutral” rating and $10 price target. The stock closed at $8.73, down 32 cents, on May 28.

Roth Capital Partners launched coverage of Corvus Pharmaceuticals (NASDAQ:CRVS) with a “buy” rating and price target of $6. The stock closed at $3.90 on May 28.

Analyst Marc Goodman of SVB Leerink has assumed coverage of Alder BioPharmaceuticals (NASDAQ:ALDR) with an “outperform” rating and $21 price target. The stock closed at $11.06 on May 24.

Novo Holdings A/S has agreed to invest up to £53.5 million in Oxford Biomedica plc (LSE:OXB) in return for new ordinary shares, representing up to 10.1% of the outstanding shares after a capital increase.

Canaccord Genuity initiated coverage of TransMedics Group (NASDAQ:TMDX) with a “buy” rating and price target of $37. The stock closed at $28.88 on May 24.

Mackie Research Capital downgraded Medicure (TSXV:MPH) to “hold from “buy” and cuts its price target to $6.50 from $7.60 after the company reported weaker than expected first quarter results. The stock closed at $5.99...

Paradigm launched coverage of Cansortium (CSE:TIUM) with a “buy” rating and a price target between $2.40 and $3.40. The stock closed at $1.59 on May 23.

H.C. Wainwright raised its price target for Aurinia Pharmaceuticals (NASDAQ:AUPH) to $25 from $15 after assessing the value of the company’s recently-received new dosing regimen patent. The stock closed at $6.49 on May...

H.C. Wainwright launched coverage of Aeglea BioTherapeutics (NASDAQ:AGLE) with a “buy” rating and $20 price target. The stock closed at $6.92 on May 21.

BTIG launched coverage of Matinas BioPharma Holdings (NYSE AMER:MTNB) with a “buy” rating and $5 price target. The stock closed at 94 cents on May 16.

Alliance Global Partners launched coverage of T2 Biosystems (NASDAQ:TTOO) with a “buy” rating and price target of $5.00. The stock closed at $2.62 on May 15.

BTIG downgraded electroCore (NASDAQ:ECOR) to a “neutral” rating following the company’s release of its first quarter 2019 results. The stock closed at $5.33 on May 14.

BTIG upgraded TransEnterix (NASDAQ:TRXC) to “buy” from “neutral” with a price target of $3, saying it sees more upside potential than downside risk at current share prices.

Roth Capital partners launched coverage of Seelos Therapeutics (NASDAQ:SEEL) with a “buy” rating and $8 price target. The stock closed at $2.71 on May 13.

BTIG initiated coverage of MannKind (NASDAQ:MNKD) with a “buy” rating and price target of $3. The stock closed at $1.23 on May 13.

Alliance Global Partners launched coverage of Canopy Growth (TSX:WEED; NYSE:CGC) with a “buy” rating and $75 price target. The stock closed at $63.78 on May 10.

SVB Leerink launched coverage of Turning Point Therapeutics (NASDAQ:TPTX) with an “outperform” rating and $42 price target. The stock closed at $32.12 on May 10.

SVB Leerink initiated coverage of Hookipa Pharma (NASDAQ:HOOK) with an “outperform” rating and $20 price target. The stock closed at $13.85 on May 10.